Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an... Research Beam Model: Research Beam Product ID: 2649117 2500 USD New
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017
 
 

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017

  • Category : Pharmaceuticals
  • Published On : September   2017
  • Pages : 970
  • Publisher : GlobalData
 
 
 
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials 20
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials 32
Prominent Drugs 34
Clinical Trial Profile Snapshots 35
Appendix 967
Abbreviations 967
Definitions 967
Research Methodology 968
Secondary Research 968
About GlobalData 969
Contact Us 969
Disclaimer 969
Source 970
List of Tables
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2017* 7
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 17
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 21
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34List of Figures
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2017* 16
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2017* 20
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
GlobalData Methodology 968
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT